Manifestation of pathognomonic signs in modeling diabetes mellitus with streptozotocin in BALB/c mice
https://doi.org/10.37489/2587-7836-2022-4-43-49
Abstract
Relevance. Diabetes mellitus is a widespread, socially significant disease. In this regard, it is important to obtain an experimental model that precedes subsequent experiments on pharmacological screening and/or study of the mechanism of action of antidiabetic agents.
The aim of this work was a comparative assessment of the manifestation of hyperglycemia, DNA damage, and morphology of internal organs in BALB/c mice in the modeling of diabetes mellitus by a single administration of streptozotocin at a dose of 200 mg/kg and its fractional, five-day administration at a rate of 40 mg/kg per day.
Methods. Streptozotocin was used as an inducer of diabetes. The drug was administered to mice once at a dose of 200 mg/kg or 5 times daily at a dose of 40 mg/kg. We monitored hyperglycemia, DNA damage in the cells of the brain, liver, kidneys, pancreas and testes, and also assessed the microscopic picture of individual internal organs, including the pancreas.
Results. In both variants of the experiment, the reproduction of pathognomonic signs of diabetes mellitus is traced. They are somewhat more clearly seen in the variant of the experiment with a fractional, five-day administration of streptozotocin in single doses of 40 mg/kg.
About the Authors
A. V. Sorokina
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Sorokina Alexandra V., PhD, Cand. Sci. Biology, Leading researcher of the laboratory of drug toxicology
Moscow
A. K. Zhanataev
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Zhanataev Alii K., PhD, Cand. Sci. Biology, leading researcher of the laboratory of pharmacology of mutagenesis
SPIN code: 7070-0510
Moscow
Z. V. Chayka
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Chayka Zlata V., Research scientist of the laboratory of pharmacology of mutagenesis
SPIN code: 1680-2370
Moscow
I. A. Miroshkina
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Miroshkina Irina A., Research scientist of the laboratory of drug toxicology
SPIN code: 4697-7938
Moscow
A. A. Lisitsyn
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Lisitsyn Artem A., engineer of the laboratory of pharmacology of Mutagenesis
SPIN code: 7857-1860
Moscow
A. D. Durnev
FSBI «Zakusov Institute of Pharmacology»
Russian Federation
Russian Federation
Durnev Andrey D., Dr. Sci (Med.), professor, corresponding member RAS, Head of the department of drug toxicology
SPIN code: 8426-0380
Moscow
References
1. Zheng Y, Ley SH, Hu FB. Global etiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018 Feb;14(2):88–98. DOI: 10.1038/nrendo.2017.151.
2. Tinajero MG, Malik VS. An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective. Endocrinol Metab Clin North Am. 2021 Sep;50(3):337–355. DOI: 10.1016/j.ecl.2021.05.013.
3. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014 Feb;103(2):137–149. DOI: 10.1016/j.diabres.2013.11.002.
4. Спасов А.А., Воронкова М.П., Снигур Г.Л., Чепляева Н.И., Чепурнова М.В. Экспериментальная модель сахарного диабета типа 2. Биомедицина. 2011;(3):12–18.
5. Озерова И.В., Тарабан К.В., Ягубова С.С., Островская Р.У. Современное состояние проблемы моделирования сахарного диабета. Экспериментальная и клиническая фармакология. 2017;80(12):35–43.
6. Islam MS, Wilson RD. Experimentally induced rodent models of type 2 diabetes. Methods Mol Biol. 2012;933:161–174. DOI: 10.1007/978-1-62703-068-7_10.
7. Furman BL. Streptozotocin-Induced Diabetic Modelsin Mice and Rats. Curr Protoc Pharmacol. 2015;70:5.47.1-5.47.20. DOI: 10.1002/0471141755.ph0547s70.
8. Дурнев А.Д., Меркулов В.А., Жанатаев А.К., Никитина В.А., Воронина Е.С., Середенин С.Б. Методические рекомендации по оценке ДНК-повреждений методом щелочного гель-электрофореза отдельных клеток в фармакологических исследованиях. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К; 2012.
9. Жанатаев А.К., Анисина Е.А., Чайка З.В., Мирошкина И.А., Дурнев А.Д. Феномен атипичных ДНК-комет. Цитология. 2017; 59(3):163–168.
10. Møller P, Loft S. Statistical analysis of comet assay results. Front Genet. 2014;5:292. DOI: 10.3389/fgene.2014.00292.
11. Еремина Н.В., Жанатаев А.К., Лисицын А.А., Дурнев А.Д. Генотоксические маркеры у больных сахарным диабетом (обзор литературы). Экологическая генетика. 2021;19(2):143–168.
12. Островская Р.У., Ягубова С.С., Жанатаев А.К., Анисина Е.А., Гудашева Т.А., Дурнев А.Д. Нейропротективный дипептид ноопепт предотвращает повреждения ДНК на модели преддиабета у мышей. Бюллетень экспериментальной биологии и медицины. 2019;168(8):185–190.
Review
For citations:
Sorokina A.V., Zhanataev A.K., Chayka Z.V., Miroshkina I.A., Lisitsyn A.A., Durnev A.D. Manifestation of pathognomonic signs in modeling diabetes mellitus with streptozotocin in BALB/c mice. Pharmacokinetics and Pharmacodynamics. 2022;(4):43-49. (In Russ.) https://doi.org/10.37489/2587-7836-2022-4-43-49
Views:
597
Email this article 